Brief: Kezar Life Sciences Says Preliminarily Estimates That Cash, Equivalents And Marketable Securities As Of June 30, 2022 Were Approximately $307 Million
July 11 (Reuters) - Kezar Life Sciences Inc KZR.O :
* KEZAR LIFE SCIENCES - PRELIMINARILY ESTIMATES THAT ITS
CASH,
EQUIVALENTS AND MARKETABLE SECURITIES AS OF JUNE 30, 2022 WERE
APPROXIMATELY $307 MILLION
Further company coverage: KZR.O
Recent news on Kezar Life Sciences
See all newsNASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. STOCKS ON THE MOVE-Sysco, Crowdstrike, GM